Company intelligence / Profile preview
Arbor Biotechnologies
Cambridge, Massachusetts, USAarbor.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ABO‑101 demonstrated promising in vivo non-human primate data supporting its advancement into clinical trials for PH1. The company’s pipeline includes additional preclinical programs targeting ALS via STMN2 disruption and cardiometabolic disease via PCSK9 silencing using proprietary compact nucleases.
- Therapeutic areas
- Rare DiseasesNeurologyCardiovascular
- Modalities
- In vivo gene editing (CRISPR-based)Programmable DNA editors (including novel nucleases such as Cas12i2 and ABR series)Ex vivo cell therapy platforms
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Vertex Pharmaceuticals – research collaboration/licensing for ex vivo engineered cell therapiesLonza – licensing deal for technologyEdigene – license agreement to advance ex vivo engineered cell therapy programsPartnership with 4D Molecular Therapeutics (“4DMT”) to co-develop/commercialize CNS genetic medicines
Beyond the preview
Go deeper on Arbor Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arbor Biotechnologies.